Artios Pharma
Artios Pharma Limited is a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer. Artios is actively developing a pipeline of highly promising potentially best-in-class and first-in-class DDR therapies identified from a global network of leading researchers in the DDR field, including through Cancer Research UK.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Live
Website
www.artiospharma.com
Related News
Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development
Artios Pharma bolsters Board of Directors with appointment of Chris Liu, PhD
Artios Pharma strengthens financial leadership with appointment of Christine Silverstein as Chief Financial Officer
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.